Stock Events

Stock Events

CytoMed Therapeutics 

$0.8899
7
+$0.01+1.11% 15:50 Today

Statistics

Day High
0.93
Day Low
0.8884
52W High
3.68
52W Low
0.68
Volume
12,212
Avg. Volume
79,820
Mkt Cap
10.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

13NovExpected
Q1 2024
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Next
-0.07
0.26
0.6
0.93
Expected EPS
N/A
Actual EPS
N/A

Financials

-1,229.66%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
253,340.79Revenue
-3.12MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow GDTC. It's not an investment recommendation.
Goldgroup Mining
2
GORO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that develops similar therapies in the field of immunology and infectious diseases, directly competing with CytoMed's product lines.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments in areas that overlap with CytoMed's research in immune modulation and targeted therapies.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals is known for its innovation in biotechnology, particularly in monoclonal antibodies, a field that competes with CytoMed's biologic therapies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals engages in developing and commercializing therapies for treating cystic fibrosis and other serious diseases, competing in the specialty biotech sector alongside CytoMed.
Biogen
BIIB
Mkt Cap32.28B
Biogen's focus on advanced biologics for neurological diseases and its expansion into immunology make it a direct competitor in the biopharmaceutical space.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in similar therapeutic areas including immunology and oncology, directly competing with CytoMed's research and development efforts.
Merck
MRK
Mkt Cap366B
Merck is a global healthcare company that develops prescription medicines and biologic therapies, competing across several of CytoMed's key areas.
Pfizer
PFE
Mkt Cap159.36B
Pfizer's broad range of biopharmaceutical products and its investment in biotechnology research make it a competitor in multiple therapeutic areas covered by CytoMed.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that produces drugs in nearly all of the same categories as CytoMed, making it a significant competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates globally in biopharmaceuticals, focusing on several of the same disease areas as CytoMed, particularly in oncology and respiratory diseases.

About

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Show more...
CEO
Chee Kong Choo
Employees
42
Country
Singapore
ISIN
SGXZ17669631
WKN
000A3D4GB

Listings

XNAS
US
GDTC
F
DE
F98.F
BOATS
BOATS
GDTC.BOATS

0 Comments

Share your thoughts

FAQ

What is CytoMed Therapeutics stock price today?▼
The current price of GDTC is $0.89 USD — it has increased by +1.11% in the past 24 hours. Watch CytoMed Therapeutics stock price performance more closely on the chart.
What is CytoMed Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange CytoMed Therapeutics stocks are traded under the ticker GDTC.
Is CytoMed Therapeutics stock price growing?▼
GDTC stock has fallen by -3.27% compared to the previous week, the month change is a +4.44% rise, over the last year CytoMed Therapeutics has showed a -53.16% decrease.
What is CytoMed Therapeutics market cap?▼
Today CytoMed Therapeutics has the market capitalization of 10.53M
When is the next CytoMed Therapeutics earnings date?▼
CytoMed Therapeutics is going to release the next earnings report on November 13, 2026.
What is CytoMed Therapeutics revenue for the last year?▼
CytoMed Therapeutics revenue for the last year amounts to 253,340.79 USD.
What is CytoMed Therapeutics net income for the last year?▼
GDTC net income for the last year is -3.12M USD.
How many employees does CytoMed Therapeutics have?▼
As of September 04, 2026, the company has 42 employees.
In which sector is CytoMed Therapeutics located?▼
CytoMed Therapeutics operates in the Health & Wellness sector.
When did CytoMed Therapeutics complete a stock split?▼
CytoMed Therapeutics has not had any recent stock splits.
Where is CytoMed Therapeutics headquartered?▼
CytoMed Therapeutics is headquartered in Singapore, Singapore.